A Pilot Study of Peptide Vaccines for VEGF Receptor 1 and 2 in Patients With Recurrent/Progressive High Grade Glioma

Oncotarget - United States
doi 10.18632/oncotarget.25131
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Timing of Surgery and Bevacizumab Therapy in Neurosurgical Patients With Recurrent High Grade Glioma

Journal of Clinical Neuroscience
MedicineSurgeryNeurologyPhysiology
2015English

Phase II Study of Bevacizumab and Vorinostat for Patients With Recurrent World Health Organization Grade 4 Malignant Glioma

Oncologist
Cancer ResearchMedicineOncology
2017English

Repeatability of 18 F-FLT PET in a Multicenter Study of Patients With High-Grade Glioma

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Use of Metformin and Survival of Patients With High-Grade Glioma

International Journal of Cancer
Cancer ResearchOncology
2018English

Combination of 6-Thioguanine, Capecitabine, and Celecoxib With Temozolomide or Lomustine for Recurrent High-Grade Glioma

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2010English

The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients With High-Grade Glioma

Academic Radiology
Nuclear MedicineRadiologyImaging
2016English

Impact of Health-Related Quality of Life and Fatigue on Survival of Recurrent High-Grade Glioma Patients

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2014English

The Information and Support Needs of Patients Diagnosed With High Grade Glioma

Patient Education and Counseling
Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy